NVN Liquidation Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Scott Plesha

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	1.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	keine Daten

Jüngste Management Updates

Recent updates

Geschäftsführer

Scott Plesha (58 yo)

less than a year

Amtszeit

Mr. Scott M. Plesha is Chief Executive Officer of Ligand Pharmaceuticals Incorporated from April 2024. Mr. Plesha had been the President of BioDelivery Sciences International, Inc. since December 2017 and...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
John Gay	Chief Financial Officer	5.3yrs	US$568.23k	0.17% $ 0.05
Scott Plesha	CEO & Director	less than a year	keine Daten	keine Daten
Carri Geer	Senior VP & CTO	5.3yrs	keine Daten	keine Daten
Sai Rangarao	Senior VP	less than a year	keine Daten	keine Daten
Tomoko Maeda-Chubachi	Chief Medical Officer	2.8yrs	keine Daten	keine Daten
Melvin Whitehead	Senior Vice President of Manufacturing Operations	less than a year	keine Daten	keine Daten

1.6yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: 0A4PDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.6 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

NVN Liquidation Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.71 loss in 1Q 2022)

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.74 loss in FY 2021)

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Forecast to breakeven in 2025

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.39 loss in 2Q 2021)

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

First quarter 2022 earnings released: US$0.71 loss per share (vs US$0.60 loss in 1Q 2021)

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.63 loss in 3Q 2020)

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit